The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Chronic Obstructive Pulmonary Disorder (COPD)-Global Market Insights and Sales Trends 2024
Synopsis
The global Chronic Obstructive Pulmonary Disorder (COPD) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Chronic Obstructive Pulmonary Disorder (COPD) in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Chronic Obstructive Pulmonary Disorder (COPD) market. Short-Acting Bronchodilators, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Chronic Obstructive Pulmonary Disorder (COPD) market, driven by demand from China, the second largest economy with some signs of stabilising, the Chronic Obstructive Pulmonary Disorder (COPD) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chronic Obstructive Pulmonary Disorder (COPD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chronic Obstructive Pulmonary Disorder (COPD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chronic Obstructive Pulmonary Disorder (COPD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chronic Obstructive Pulmonary Disorder (COPD) covered in this report include GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc.
The global Chronic Obstructive Pulmonary Disorder (COPD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Global Chronic Obstructive Pulmonary Disorder (COPD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chronic Obstructive Pulmonary Disorder (COPD) market, Segment by Type:
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Global Chronic Obstructive Pulmonary Disorder (COPD) market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Chronic Obstructive Pulmonary Disorder (COPD) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Chronic Obstructive Pulmonary Disorder (COPD) in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Chronic Obstructive Pulmonary Disorder (COPD) market. Short-Acting Bronchodilators, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Chronic Obstructive Pulmonary Disorder (COPD) market, driven by demand from China, the second largest economy with some signs of stabilising, the Chronic Obstructive Pulmonary Disorder (COPD) market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chronic Obstructive Pulmonary Disorder (COPD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chronic Obstructive Pulmonary Disorder (COPD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chronic Obstructive Pulmonary Disorder (COPD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chronic Obstructive Pulmonary Disorder (COPD) covered in this report include GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc.
The global Chronic Obstructive Pulmonary Disorder (COPD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Global Chronic Obstructive Pulmonary Disorder (COPD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chronic Obstructive Pulmonary Disorder (COPD) market, Segment by Type:
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Global Chronic Obstructive Pulmonary Disorder (COPD) market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Chronic Obstructive Pulmonary Disorder (COPD)
1.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Overview
1.1.1 Chronic Obstructive Pulmonary Disorder (COPD) Product Scope
1.1.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Status and Outlook
1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2029)
1.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2018-2023)
1.5 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
1.6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
1.6.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
1.6.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
1.6.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
1.6.5 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)
2 Chronic Obstructive Pulmonary Disorder (COPD) Market by Type
2.1 Introduction
2.1.1 Short-Acting Bronchodilators
2.1.2 Corticosteroids
2.1.3 Methylxanthines
2.1.4 Long-Acting Bronchodilators
2.1.5 Phosphodiesterase-4 Inhibitors
2.1.6 Others
2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2018-2023)
2.2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Type (2018-2029)
3 Chronic Obstructive Pulmonary Disorder (COPD) Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2018-2023)
3.2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue Breakdown by Application (2018-2029)
4 Chronic Obstructive Pulmonary Disorder (COPD) Competition Analysis by Players
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2022)
4.3 Date of Key Players Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
4.4 Global Top Players Chronic Obstructive Pulmonary Disorder (COPD) Headquarters and Area Served
4.5 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
4.6 Competitive Status
4.6.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GSK
5.1.1 GSK Profile
5.1.2 GSK Main Business
5.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.1.4 GSK Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.1.5 GSK Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.2.4 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.3.4 Merck Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.4.4 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.5.4 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.5.5 AstraZeneca Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.6.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Teva Pharmaceuticals
5.7.1 Teva Pharmaceuticals Profile
5.7.2 Teva Pharmaceuticals Main Business
5.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.7.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.7.5 Teva Pharmaceuticals Recent Developments
5.8 Ario Pharma
5.8.1 Ario Pharma Profile
5.8.2 Ario Pharma Main Business
5.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.8.4 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.8.5 Ario Pharma Recent Developments
5.9 Roche
5.9.1 Roche Profile
5.9.2 Roche Main Business
5.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.9.4 Roche Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.9.5 Roche Recent Developments
5.10 Ache
5.10.1 Ache Profile
5.10.2 Ache Main Business
5.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.10.4 Ache Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.10.5 Ache Recent Developments
5.11 Almirall
5.11.1 Almirall Profile
5.11.2 Almirall Main Business
5.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.11.4 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.11.5 Almirall Recent Developments
5.12 Aquinox Pharmaceuticals
5.12.1 Aquinox Pharmaceuticals Profile
5.12.2 Aquinox Pharmaceuticals Main Business
5.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.12.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.12.5 Aquinox Pharmaceuticals Recent Developments
5.13 Asmacure
5.13.1 Asmacure Profile
5.13.2 Asmacure Main Business
5.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.13.4 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.13.5 Asmacure Recent Developments
5.14 Astellas Pharma
5.14.1 Astellas Pharma Profile
5.14.2 Astellas Pharma Main Business
5.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Products, Services and Solutions
5.14.4 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue (US$ Million) & (2018-2023)
5.14.5 Astellas Pharma Recent Developments
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics
11.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends
11.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
11.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
11.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
